# US 2023/0072313 A1 · Cyclic pantetheine derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0072313 A1
- Document ID: US20230072313A1
- Status: Published application
- Kind: A1
- Application number: 17/298,658
- Filed: 2019-12-02
- Published: 2023-03-09
- Earliest claimed: 2018-11-30
- Assignees: VectivBio Comet AG
- Applicants: Comet Therapeutics, Inc.
- Inventors: Arthur George TAVERAS; Enej KUSCER; Angelina Roberta SEKIRNIK; Dharini SHAH; Mercedes VALLS SERON
- Web page: https://patentgrep.com/patent/US20230072313A1

## CPC

- A61K 31/665: having oxygen as a ring hetero atom, e.g. fosfomycin
- C07F 9/65742: {non-condensed with carbocyclic rings or heterocyclic rings or ring systems}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07C 323/41: Y being a hydrogen or an acyclic carbon atom
- C07C 323/52: the carbon skeleton being acyclic and saturated
- C07C 327/22: having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 327/30: having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C 327/32: having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 327/34: with amino groups bound to the same hydrocarbon radicals
- C07D 207/28: 2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
- C07D 307/33: in position 2, the oxygen atom being in its keto or unsubstituted enol form
- C07D 307/58: One oxygen atom, e.g. butenolide
- C07D 317/30: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 317/34: Oxygen atoms
- C07D 317/46: condensed with one six-membered ring
- C07D 319/06: not condensed with other rings
- C07D 321/08: 1,4-Dioxepines; Hydrogenated 1,4-dioxepines
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 491/113: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 493/10: Spiro-condensed systems
- C07F 7/081: {comprising at least one atom selected from the elements N, O, halogen, S, Se or Te}
- C07F 9/091: {with hydroxyalkyl compounds with further substituents on alkyl}
- C07F 9/12: with hydroxyaryl compounds
- C07F 9/657154: {Cyclic esteramides of oxyacids of phosphorus}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to compounds of Formula (P) or (II′-0): (Formulae (I′), (II′-0)), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

## Claims

### Claim 1

A compound of Formula (I′) or (II′-0):
or a pharmaceutically acceptable salt or solvate thereof, wherein:
each T is independently
each Rt is independently R1, R1a, R1b or R1c; or
two Rt, together with the one or more intervening atoms they are attached to, form a C3-C12 cycloalkyl or C3-C12 heterocycloalkyl, wherein C3-C12 cycloalkyl or C3-C12 heterocycloalkyl is optionally substituted with one or more R1a;
t is an integer ranging from 0 to 5;
R1 is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkenyl, —C(═O)R1b, —C(═O)R1z, —C(═O)—(CH═CH)n—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)CH(R1a)—[C(═O)CH(R1a)]p—[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]p—[CH2]q—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH(OR1c)—CH2]r[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]r—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)OR1c, —C(═O)N(R1c)2, —C(═O)—CH═CH—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)OR1c, —C(═O)—CH2CH2—C(═O)OR1c, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)R1z, —C(═O)—CH2CH2—C(═O)R1z, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)R1z, —SR1d,
wherein the C1-C20 alkyl, C2-C20 alkenyl or C2-C20 alkynyl is optionally substituted with one or more R1a, and wherein one or more methylene moieties in the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl are optionally replaced by one or more carbonyl moieties;
each R1a is independently H, oxo, halogen, C1-C20 alkyl, C2-C20 alkenyl, —OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, —N(R1c)2, —N(R1c)C(═O)R1b, —N(R1c)C(═O)R1z, —N(R1c)C(═O)OR1c, —OC(═O)R1b, —OC(═O)R1z, —OC(═O)OR1c, —OSi(R1g)3, —SC(═O)R1b, —SC(═O)R1z, —SC(═O)OR1c, —SC(═O)N(R1c)2, —C(═O)R1b, —C(═O)R1z, —SR1d, or R1g, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1e;
each R1b is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —(CH2)q—C(═O)OR1c, —CH2—C(═O)—(CH2)q—C(═O)OR1c, —CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, C(═O)OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1e;
each R1c is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1c; or two R1c together with the one or more intervening atoms to which they are connected, form C3-C12 cycloalkyl or C3-C12 heterocycloalkyl, wherein the C3-C12 cycloalkyl or C3-C12 heterocycloalkyl is optionally substituted with one or more R1e;
each R1d is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C10 cycloalkyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
each R1e is independently H, halogen, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, —N(R1g)2, —N(R1g)C(═O)R1f, —N(R1g)C(═O)R1z, —N(R1g)C(═O)OR1g, —OC(═O)R1f, —OC(═O)R1z, —OC(═O)OR1g, —OSi(R1g)3, —SR1g, —N+(R1g)3, —SC(═O)R1f, —SC(═O)R1z, —SC(═O)OR1g, —SC(═O)N(R1g)2, —C(═O)R1f, —C(═O)R1z, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
each R1f is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —OSi(R1g)3, —CH2C(═O)OR1g, —CH═CH—C(═O)OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, or R1g, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1g;
each R1g is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C2 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C2 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1z;
each R1z is independently
each n is independently an integer ranging from 0 to 20;
each p is independently an integer ranging from 0 to 20;
each q is independently an integer ranging from 0 to 20;
each r is independently an integer ranging from 0 to 20;
each X is independently —OR1c, —SR1c, —N(R1c)2,
or R1z; and
Y is a bond or C1-C20 alkyl optionally substituted with one or more R1e.

### Claim 2

A compound of Formula (I′) or (II′):
or a pharmaceutically acceptable salt or solvate thereof, wherein:
each T is independently
each Rt is independently R1, R1a, or R1b; or
two Rt, together with the one or more intervening atoms they are attached to, form a C3-C12 cycloalkyl or C3-C12 heterocycloalkyl, wherein C3-C12 cycloalkyl or C3-C12 heterocycloalkyl is optionally substituted with one or more R1a;
t is an integer ranging from 0 to 5;
R1 is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —C(═O)R1b, —C(═O)R1z, —C(═O)—(CH═CH)n—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)CH(R1a)—[C(═O)CH(R1a)]p—[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]p—[CH2]q—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH(OR1c)—CH2]r[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]r—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)OR1c, —C(═O)N(R1c)2, —C(═O)—CH═CH—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)OR1c, —C(═O)—CH2CH2—C(═O)OR1c, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)R1z, —C(═O)—CH2CH2—C(═O)R1z, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)R1z, —SR1d,
wherein the C1-C20 alkyl, C2-C20 alkenyl or C2-C20 alkynyl is optionally substituted with one or more R1a, and wherein one or more methylene moieties in the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl are optionally replaced by one or more carbonyl moieties;
each R1a is independently H, oxo, halogen, C1-C20 alkyl, C2-C20 alkenyl, —OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, —N(R1c)2, —N(R1c)C(═O)R1b, —N(R1c)C(═O)R1z, —N(R1c)C(═O)OR1c, —OC(═O)R1b, —OC(═O)R1z, —OC(═O)OR1c, —SC(═O)R1b, —SC(═O)R1z, —SC(═O)OR1c, —SC(═O)N(R1c)2, —C(═O)R1b, —C(═O)R1z, —SR1d, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1d;
each R1b is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —(CH2)q—C(═O)OR1c, —CH2—C(═O)—(CH2)q—C(═O)OR1c, —CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —CH—H—C(═O)OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1e;
each R1c is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
each R1d is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C10 cycloalkyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
each R1e is independently H, halogen, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, —N(R1g)2, —N(R1g)C(═O)R1f, —N(R1g)C(═O)R1z, —N(R1g)C(═O)OR1g, —OC(═O)R1f, —OC(═O)R1z, —OC(═O)OR1g, —SR1g, —N+(R1g)3, —SC(═O)R1f, —SC(═O)R1z, —SC(═O)OR1g, —SC(═O)N(R1g)2, —C(═O)R1f, —C(═O)R1z, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
each R1f is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —CH2C(═O)OR1g, —CH═CH—C(═O)OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
each R1g is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C2 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1z;
each R1z is independently
each n is independently an integer ranging from 0 to 20;
each p is independently an integer ranging from 0 to 20;
each q is independently an integer ranging from 0 to 20;
each r is independently an integer ranging from 0 to 20; and
each X is independently —OR1c, —SR1c, —N(R1c)2,
or R1z.

### Claim 3

A compound of Formula (I), (II), (III), (IV), (V), or (VI):
or a pharmaceutically acceptable salt or solvate thereof, wherein:
R1 is H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —C(═O)R1b, —C(═O)R1z, —C(═O)—(CH═CH)n—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]p—[CH2]q—R1a, —C(═O)CH2—[C(═O)CH2]p—[CH(OR1c)—CH2]r[CH2]q—R1a, —C(═O)CH2—[CH(OR1c)—CH2]r—[C(═O)CH2]p—[CH2]q—R1a, —C(═O)OR1c, —C(═O)N(R1c)2, —C(═O)—CH═CH—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)OR1c, —C(═O)—CH2CH2—C(═O)OR1c, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —C(═O)—[CH2]q—C(═O)R1z, —C(═O)—CH2CH2—C(═O)R1z, —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)R1z, —SR1d,
wherein the C1-C20 alkyl, C2-C20 alkenyl or C2-C20 alkynyl is optionally substituted with one or more R1a, and wherein one or more methylene moieties in the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl are optionally replaced by one or more carbonyl moieties;
each R1a is independently H, oxo, halogen, C1-C20 alkyl, C2-C20 alkenyl, —OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, —N(R1c)2, —N(R1c)C(═O)R1b, —N(R1c)C(═O)R1z, —N(R1c)C(═O)OR1c, —OC(═O)R1b, —OC(═O)R1z, —OC(═O)OR1c, —SC(═O)R1b, —SC(═O)R1z, —SC(═O)OR1c, —SC(═O)N(R1c)2, —C(═O)R1b, —C(═O)R1z, —SR1d, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1c;
each R1b is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —(CH2)q—C(═O)OR1c, —CH2—C(═O)—(CH2)q—C(═O)OR1c, —CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c, —CH═CH—C(═O)OR1c, —C(═O)OR1c, —C(═O)N(R1c)2, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1e;
each R1c is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
each R1d is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C10 cycloalkyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12, heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1e;
each R1e is independently H, halogen, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, —N(R1g)2, —N(R1g)C(═O)R1f, —N(R1g)C(═O)R1z, —N(R1g)C(═O)OR1g, —OC(═O)R1c, —OC(═O)R1z, —OC(═O)OR1g, —SR1g, —N+(R1g)3, —SC(═O)R1f, —SC(═O)R1z, —SC(═O)OR1g, —SC(═O)N(R1g)2, —C(═O)R1f, —C(═O)R1z, or R1z, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
each R1f is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, —CH2C(═O)OR1g, —CH═CH—C(═O)OR1g, —C(═O)OR1g, —C(═O)N(R1g)2, or R1g, wherein the C1-C20 alkyl, C2-C20 alkenyl, or C2-C20 alkynyl is optionally substituted with one or more R1z;
each R1g is independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl), wherein the C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C12 cycloalkyl, C3-C12 heterocycloalkyl, C3-C12 aryl, C3-C12 heteroaryl, —(C1-C20 alkyl)-(C3-C12 cycloalkyl), —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl), —(C1-C20 alkyl)-(C3-C12 aryl), or —(C1-C20 alkyl)-(C3-C12 heteroaryl) is optionally substituted with one or more R1f,
each R1f is independently
each n is independently an integer ranging from 0 to 20;
each p is independently an integer ranging from 0 to 20;
each q is independently an integer ranging from 0 to 20;
each r is independently an integer ranging from 0 to 20; and
each X is independently —OR1c, —SR1c, —N(R1c)2,

### Claim 4

The compound of any one of the preceding claims, wherein R1 is C1-20 alkyl.

### Claim 5

The compound of any one of the preceding claims, wherein R1 is —C(═O)R1b.

### Claim 6

The compound of any one of the preceding claims, wherein R1 is —C(═O)R1z.

### Claim 7

The compound of any one of the preceding claims, wherein R1 is

### Claim 8

The compound any one of the preceding claims, wherein R1 is

### Claim 9

The compound of any one of the preceding claims, wherein R1 is —C(═O)—(CH═CH)n—R1a.

### Claim 10

The compound of an one of the preceding claims, wherein R1 is

### Claim 11

The compound of any one of the preceding claims, wherein R1 is [C(═O)CH2]p—[CH2]q—R1a.

### Claim 12

The compound of any one of the preceding claims, wherein R1 is

### Claim 13

The compound of any one of the preceding claims, wherein R1 is

### Claim 14

The compound of any one of the preceding claims, wherein R1 is

### Claim 15

The compound of any one of the preceding claims, wherein R1 is

### Claim 16

The compound of any one of the preceding claims, wherein R1 is

### Claim 17

The compound of any one of the preceding claims, wherein R1 is

### Claim 18

The compound of any one of the preceding claims, wherein R1 is

### Claim 19

The compound of any one of the preceding claims, wherein R1 is

### Claim 20

The compound of any one of the preceding claims, wherein R1 is

### Claim 21

The compound of any one of the preceding claims, wherein R1 is

### Claim 22

The compound of any one of the preceding claims, wherein R1 is

### Claim 23

The compound of any one of the preceding claims, wherein R1 is

### Claim 24

The compound of any one of the preceding claims, wherein R1 is

### Claim 25

The compound of any one of the preceding claims, wherein R1 is

### Claim 26

The compound of any one of the preceding claims, wherein R1 is —C(═O)CH(R1a)—[C(═O)CH(R1a)]p—[CH2]q—R1a.

### Claim 27

The compound of any one of the preceding claims, wherein R1 is

### Claim 28

The compound of any one of the preceding claims,

### Claim 29

The compound of any one of the preceding claims, wherein R1 is

### Claim 30

The compound of any one of the preceding claims, wherein R1 is

### Claim 31

The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[CH(OR1c)—CH2]p—[CH2]q—R1a.

### Claim 32

The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[C(═O)CH2]p—[CH(OR1c)—CH2]r—[CH2]q—R1a.

### Claim 33

The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[CH(OR1c)—CH2]r[C(═O)CH2]p—[CH2]q—R1a.

### Claim 34

The compound of any one of the preceding claims, wherein R1 is —C(═O)OR1c.

### Claim 35

The compound of any one of the preceding claims, wherein R1 is C(═O)N(R1c)2.

### Claim 36

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH═CH—C(═O)OR1c.

### Claim 37

The compound of any one of the preceding claims, wherein R1 is —C(═O)—[CH2]q—C(═O)OR1c.

### Claim 38

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)OR1c.

### Claim 39

The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c.

### Claim 40

The compound of any one of the preceding claims, wherein R1 is —C(═O)—[CH2]q—C(═O)R1z.

### Claim 41

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)R1z.

### Claim 42

The compound of any one of the preceding claims, wherein R1 is —C(═O)CH2—[C(═O)CH2]p—[CH2]q—C(═O)R1z.

### Claim 43

The compound of any one of the preceding claims, wherein R1 is

### Claim 44

The compound of any one of the preceding claims, wherein R1 is

### Claim 45

The compound of any one of the preceding claims, wherein R1 is

### Claim 46

The compound of any one of the preceding claims, wherein R1 is

### Claim 47

The compound of any one of the preceding claims, wherein R1a is H.

### Claim 48

The compound of any one of the preceding claims, wherein R1a is C1-C20 alkyl.

### Claim 49

The compound of any one of the preceding claims, wherein R1a is C2-C20 alkenyl.

### Claim 50

The compound of any one of the preceding claims, wherein R1a is —OR1c.

### Claim 51

The compound of any one of the preceding claims, wherein R1a is —C(═O)OR1c.

### Claim 52

The compound of any one of the preceding claims, wherein R1a is —C(═O)R1b.

### Claim 53

The compound of any one of the preceding claims, wherein R1a is —C(═O)R1z.

### Claim 54

The compound of any one of the preceding claims, wherein R1a is R1z.

### Claim 55

The compound of any one of the preceding claims, wherein R1b is C1-C20 alkyl.

### Claim 56

The compound of any one of the preceding claims, wherein R1b is C2-C20 alkenyl.

### Claim 57

The compound of any one of the preceding claims, wherein R1b is —(CH2)q—C(═O)OR1c.

### Claim 58

The compound of any one of the preceding claims, wherein R1b is —CH2—C(═O)—(CH2)q—C(═O)OR1c.

### Claim 59

The compound of any one of the preceding claims, wherein R1b is —CH2—[C(═O)CH2]p—[CH2]q—C(═O)OR1c.

### Claim 60

The compound of any one of the preceding claims, wherein R1b is —CH—H—C(═O)OR1c.

### Claim 61

The compound of any one of the preceding claims, wherein R1b is R1z.

### Claim 62

The compound of any one of the preceding claims, wherein R1c is H.

### Claim 63

The compound of any one of the preceding claims, wherein R1c is C1-20 alkyl.

### Claim 64

The compound of any one of the preceding claims, wherein R1c is C2-20 alkenyl.

### Claim 65

The compound of any one of the preceding claims, wherein R1c is —(C1-C20 alkyl)-(C3-C12 cycloalkyl).

### Claim 66

The compound of any one of the preceding claims, wherein R1c is —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl).

### Claim 67

The compound of any one of the preceding claims, wherein R1c is —(C1-C20 alkyl)-(C3-C12 aryl).

### Claim 68

The compound of any one of the preceding claims, wherein R1c is —(C1-C20 alkyl)-(C3-C12 heteroaryl).

### Claim 69

The compound of any one of the preceding claims, wherein R1d is H.

### Claim 70

The compound of any one of the preceding claims, wherein R1d is C1-C20 alkyl.

### Claim 71

The compound of any one of the preceding claims, wherein R1d is C2-C20 alkenyl.

### Claim 72

The compound of any one of the preceding claims, wherein R1d is C3-C12 cycloalkyl.

### Claim 73

The compound of any one of the preceding claims, wherein R1d is C3-C12 heterocycloalkyl.

### Claim 74

The compound of any one of the preceding claims, wherein R1d is C3-C12 aryl.

### Claim 75

The compound of any one of the preceding claims, wherein R1d is C3-C12 heteroaryl.

### Claim 76

The compound of any one of the preceding claims, wherein R1d is —(C1-C20 alkyl)-(C3-C12 cycloalkyl).

### Claim 77

The compound of any one of the preceding claims, wherein R1d is —(C1-C20 alkyl)-(C3-C12 heterocycloalkyl).

### Claim 78

The compound of any one of the preceding claims, wherein R1d is —(C1-C20 alkyl)-(C3-C12 aryl).

### Claim 79

The compound of any one of the preceding claims, wherein R1d is —(C1-C20 alkyl)-(C3-C12 heteroaryl).

### Claim 80

The compound of any one of the preceding claims, wherein R1e is H.

### Claim 81

The compound of any one of the preceding claims, wherein R1e is C1-C20 alkyl.

### Claim 82

The compound of any one of the preceding claims, wherein R1e is C2-C10 alkenyl.

### Claim 83

The compound of any one of the preceding claims, wherein R1e is —OR1g.

### Claim 84

The compound of any one of the preceding claims, wherein R1e is —C(═O)OR1g.

### Claim 85

The compound of any one of the preceding claims, wherein R1e is —C(═O)OR1f.

### Claim 86

The compound of any one of the preceding claims, wherein R1e is —C(═O)R1z.

### Claim 87

The compound of any one of the preceding claims, wherein R1e is —N(R1g)C(═O)R1z.

### Claim 88

The compound of any one of the preceding claims, wherein R1e is —OC(═O)R1z.

### Claim 89

The compound of any one of the preceding claims, wherein R1e is —N+(R1g)3.

### Claim 90

The compound of any one of the preceding claims, wherein R1e is R1z.

### Claim 91

The compound of any one of the preceding claims, wherein R1f is H.

### Claim 92

The compound of any one of the preceding claims, wherein R1f is C1-C20 alkyl.

### Claim 93

The compound of any one of the preceding claims, wherein R1f is C2-C20 alkenyl.

### Claim 94

The compound of any one of the preceding claims, wherein R1f is —CH2C(═O)OR1g.

### Claim 95

The compound of any one of the preceding claims, wherein R1f is —CH═CH—C(═O)OR1g.

### Claim 96

The compound of any one of the preceding claims, wherein R1f is —C(═O)OR1g.

### Claim 97

The compound of any one of the preceding claims, wherein R1f is R1z.

### Claim 98

The compound of any one of the preceding claims, wherein R1z is

### Claim 99

The compound of any one of the preceding claims, wherein R1z is

### Claim 100

The compound of any one of the preceding claims, wherein R1z is

### Claim 101

The compound of any one of the preceding claims, wherein n is 0 to 4.

### Claim 102

The compound of any one of the preceding claims, wherein n is 0.

### Claim 103

The compound of any one of the preceding claims, wherein n is 1.

### Claim 104

The compound of any one of the preceding claims, wherein n is 2.

### Claim 105

The compound of any one of the preceding claims, wherein p is 0 to 4.

### Claim 106

The compound of any one of the preceding claims, wherein p is 0.

### Claim 107

The compound of any one of the preceding claims, wherein p is 1.

### Claim 108

The compound of any one of the preceding claims, wherein p is 2.

### Claim 109

The compound of any one of the preceding claims, wherein q is 0 to 4.

### Claim 110

The compound of any one of the preceding claims, wherein q is 0.

### Claim 111

The compound of any one of the preceding claims, wherein q is 1.

### Claim 112

The compound of any one of the preceding claims, wherein q is 2.

### Claim 113

The compound of any one of the preceding claims, wherein r is 0 to 4.

### Claim 114

The compound of any one of the preceding claims, wherein r is 0.

### Claim 115

The compound of any one of the preceding claims, wherein r is 1.

### Claim 116

The compound of any one of the preceding claims, wherein r is 2.

### Claim 117

The compound of any one of the preceding claims, wherein X is —OR1c.

### Claim 118

The compound of any one of the preceding claims, wherein X is —SR1c.

### Claim 119

The compound of any one of the preceding claims, wherein X is —N(R1c)2.

### Claim 120

The compound of any one of the preceding claims, wherein X is

### Claim 121

The compound of any one of the preceding claims, wherein X is

### Claim 122

The compound of any one of the preceding claims, wherein X is

### Claim 123

The compound of any one of the preceding claims, wherein X is

### Claim 124

The compound of any one of the preceding claims, wherein X is

### Claim 125

The compound of any one of the preceding claims, wherein X is

### Claim 126

The compound of any one of the preceding claims, wherein X is

### Claim 127

The compound of any one of the preceding claims, wherein X is

### Claim 128

The compound of any one of the preceding claims, wherein X is

### Claim 129

The compound of any one of the preceding claims, wherein X is

### Claim 130

The compound of any one of the preceding claims, wherein X is

### Claim 131

The compound of any one of the preceding claims, wherein X is

### Claim 132

The compound of any one of the preceding claims, wherein X is

### Claim 133

The compound of any one of the preceding claims, wherein X is

### Claim 134

The compound of any one of the preceding claims, wherein X is R1z.

### Claim 135

The compound of any one of the preceding claims, wherein X is

### Claim 136

The compound of any one of the preceding claims, wherein X is

### Claim 137

The compound of any one of the preceding claims, wherein at least one T is

### Claim 138

The compound of any one of the preceding claims, wherein at least one T is

### Claim 139

The compound of any one of the preceding claims, wherein at least one T is

### Claim 140

The compound of any one of the preceding claims, wherein at least one T is

### Claim 141

The compound of any one of the preceding claims, wherein at least one T is

### Claim 142

The compound of any one of the preceding claims, wherein at least one T is

### Claim 143

The compound of any one of the preceding claims, wherein at least one T is

### Claim 144

The compound of any one of the preceding claims, wherein Rt is R1.

### Claim 145

The compound of any one of the preceding claims, wherein Rt is R1a.

### Claim 146

The compound of any one of the preceding claims, wherein Rt is R1b.

### Claim 147

The compound of any one of the preceding claims, wherein two Rt form a C3-C12 cycloalkyl.

### Claim 148

The compound of any one of the preceding claims, wherein two Rt form a C1-C12 heterocycloalkyl.

### Claim 149

The compound of any one of the preceding claims, wherein two Rt form a C3-C12 cycloalkyl optionally substituted with one or more R1a.

### Claim 150

The compound of any one of the preceding claims, wherein two Rt form a C3-C12 heterocycloalkyl optionally substituted with one or more R1a.

### Claim 151

The compound of any one of the preceding claims, wherein t is 1.

### Claim 152

The compound of any one of the preceding claims, wherein t is 2.

### Claim 153

The compound of any one of the preceding claims, being of Formula (I′-1) or (I′-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 154

The compound of any one of the preceding claims, wherein each T is independently

### Claim 155

The compound of any one of the preceding claims, wherein each T is independently

### Claim 156

The compound of any one of the preceding claims, wherein each T is independently

### Claim 157

The compound of any one of the preceding claims, wherein each T is independently

### Claim 158

The compound of any one of the preceding claims, wherein each T is independently

### Claim 159

The compound of any one of the preceding claims, wherein each T is independently

### Claim 160

The compound of any one of the preceding claims, wherein each T is independently

### Claim 161

The compound of any one of the preceding claims, wherein R1 is —C(═O)—R1a, —C(═O)—CH2—R1a, —C(═O)—CH2CH2—R1a or —C(═O)—CH═CH—R1a, wherein R1a is C1-C20 alkyl, —C(═O)R1b, or —C(═O)OR1c, wherein the C1-C20 alkyl is optionally substituted with one or more Rio.

### Claim 162

The compound of any one of the preceding claims, wherein R1 is —C(═O)—R1a, wherein —R1a is C1-C20 alkyl.

### Claim 163

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH3.

### Claim 164

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—R1a, wherein R1a is C1-C20 alkyl optionally substituted with one or more R1e, wherein R1e is —OH.

### Claim 165

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—R1a, wherein R1a is ethyl substituted one —OH.

### Claim 166

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—CH(OH)—CH3.

### Claim 167

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—R1a, wherein R1a is —C(═O)R1b.

### Claim 168

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—C(═O)—R1b, wherein R1b is C1-C20 alkyl.

### Claim 169

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2—C(═O)—CH3.

### Claim 170

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—R1a, wherein R1a is C1-C20 alkyl or —C(═O)OR1c

### Claim 171

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)OR1c, wherein R1c is H or C1-C20 alkyl.

### Claim 172

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)OH.

### Claim 173

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH2CH2—C(═O)OCH3.

### Claim 174

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH═CH—R1a, wherein —R1a is C1-C20 alkyl or —C(═O)OR1c.

### Claim 175

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH—H—R1a, wherein —R1a is C1-C20 alkyl.

### Claim 176

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH—H—CH3.

### Claim 177

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH═CH—C(═O)OR1c, wherein R1c is H or C1-C20 alkyl.

### Claim 178

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH—H—C(═O)OH.

### Claim 179

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH—H—C(═O)OCH3.

### Claim 180

The compound of any one of the preceding claims, wherein R1 is —C(═O)—CH3, —C(═O)—CH2—CH(OH)—CH3, —C(═O)—CH2—C(═O)—CH3, —C(═O)—CH2CH2—C(═O)OH, —C(═O)—CH2CH2—C(═O)OCH3, —C(═O)—CH═CH—CH3, —C(═O)—CH═CH—C(═O)OH, or —C(═O)—CH═CH—C(═O)OCH3.

### Claim 181

The compound of any one of the preceding claims, wherein each T is independently
and R1 is —C(═O)—R1a, —C(═O)—CH2—R1a, —C(═O)—CH2CH2—R1a or —C(═O)—CH═CH—R1a, wherein R1a is C1-C20 alkyl, —C(═O)R1b, or —C(═O)OR1c, wherein the C1-C20 alkyl is optionally substituted with one or more R1e.

### Claim 182

The compound of any one of the preceding claims, wherein each T is independently
and R1 is —C(═O)—CH3, —C(═O)—CH2—CH(OH)—CH3, —C(═O)—CH2—C(═O)—CH3, —C(═O)—CH2CH2—C(═O)OH, —C(═O)—CH2CH2—C(═O)OCH3, —C(═O)—CH═CH—CH3, —C(═O)—CH═CH—C(═O)OH, or —C(═O)—CH═CH—C(═O)OCH3.

### Claim 183

The compound of any one of the preceding claims, being of Formula (Ia′):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 184

The compound of any one of the preceding claims, being of Formula (Ia′-1) or (Ia′-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 185

The compound of any one of the preceding claims, being of Formula (Ib′):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 186

The compound of any one of the preceding claims, being of Formula (Ib′-1) or (Ib′-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 187

The compound of any one of the preceding claims, being of Formula (II′-1) or (II′-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 188

The compound of any one of the preceding claims, being of Formula (IIa′):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 189

The compound of any one of the preceding claims, being of Formula (IIa′-1) or (IIa′-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 190

The compound of any one of the preceding claims, being of Formula (IIb′):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 191

The compound of any one of the preceding claims, being of Formula (IIb′-1) or (IIb′-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 192

The compound of any one of the preceding claims, being of Formula (I-1) or (I-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 193

The compound of any one of the preceding claims, being of Formula (Iaa), (Iab), (Iac), or (Iad):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 194

The compound of any one of the preceding claims, being of Formula (Iaa-1), (Iaa-2), (Iab-1), (Iab-2), (Iac-1), (Iac-2), (Iad-1), or (Iad-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 195

The compound of any one of the preceding claims, being of Formula (Iae), (Iaf), (Iag), or (Iah):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 196

The compound of any one of the preceding claims, being of Formula (Iae-1), (Iae-2), (Iaf-1), (Iaf-2), (Iag-1), (Iag-2), (Iah-1), or (Iah-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 197

The compound of any one of the preceding claims, being of Formula (Iai), (Iaj), (Iak), (Ial), (Iam), or (Ian):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 198

The compound of any one of the preceding claims, being of Formula (Iai-1), (Iai-2), (Iaj-1), (Iaj-2), (Iak-1), (Iak-2), (Ial-1), (Ial-2), (Iam-1), (Iam-2), (Ian-1), or (Ian-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 199

The compound of any one of the preceding claims, being of Formula (Iba), (Ibb), (Ibc), or (Ibd):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 200

The compound of any one of the preceding claims, being of Formula (Iba-1), (Iba-2), (Ibb-1), (Ibb-2), (Ibc-1), (Ibc-2), or (Ibd-1), or (Ibd-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 201

The compound of any one of the preceding claims, being of Formula (Ibe), or (Ibf):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 202

The compound of any one of the preceding claims, being of Formula (Ibe-1), (Ibe-2), (Ibf-1), or (Ibf-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 203

The compound of any one of the preceding claims, being of Formula (Ibg), (Ibh), (Ibi), or (Ibj):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 204

The compound of any one of the preceding claims, being of Formula (Ibg-1), (Ibg-2), (Ibh-1), (Ibh-2), (Ibi-1), (Ibi-2), (Ibi-1), or (Ibi-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 205

The compound of any one of the preceding claims, being of Formula (Ibk), (Ibl), (Ibm), or (Ibn):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 206

The compound of any one of the preceding claims, being of Formula (Ibk-1), (Ibk-2), (Ibl-1), (Ibl-2), (Ibm-1), (Ibm-2), (Ibn-1), or (Ibn-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 207

The compound of any one of the preceding claims, being of Formula (Ibo), (Ibp), (Ibq), or (Ibr):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 208

The compound of any one of the preceding claims, being of Formula (Ibo-1), (Ibo-2), (Ibp-1), (Ibp-2), (Ibq-1), (Ibq-2), (Ibr-1), or (Ibr-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 209

The compound of any one of the preceding claims, being of Formula (II-1) or (II-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 210

The compound of any one of the preceding claims, being of Formula (IIaa), (IIab), (IIac), or (IIad):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 211

The compound of any one of the preceding claims, being of Formula (IIaa-1), (IIaa-2), (IIab-1), (IIab-2), (IIac-1), (IIac-2), (IIad-1), or (IIad-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 212

The compound of any one of the preceding claims, being of Formula (IIae), (IIaf), (IIag), or (IIah):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 213

The compound of any one of the preceding claims, being of Formula (IIae-1), (IIae-2), (IIaf-1), (IIaf-2), (IIag-1), (IIag-2), (IIah-1), or (IIah-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 214

The compound of any one of the preceding claims, being of Formula (IIai), (IIaj), (IIak), (IIal), (IIam), or (IIan):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 215

The compound of any one of the preceding claims, being of Formula (IIai-1), (IIai-2), (IIaj-1), (IIaj-2), (IIak-1), (IIak-2), (IIal-1), (IIal-2), (IIam-1), (IIam-2), (IIan-1), or (IIan-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 216

The compound of any one of the preceding claims, being of Formula (III-1) or (III-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 217

The compound of any one of the preceding claims, being of Formula (IV-1) or (IV-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 218

The compound of any one of the preceding claims, being of Formula (V-1) or (V-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 219

The compound of any one of the preceding claims, being of Formula (VI-1) or (VI-2):
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 220

The compound of any one of the preceding claims, being selected from the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

### Claim 221

The compound of any one of the preceding claims, being selected from Compound Nos. 1-446 and pharmaceutically acceptable salts thereof.

### Claim 222

The compound of any one of the preceding claims, being selected from Compound Nos. 447-516 and pharmaceutically acceptable salts thereof.

### Claim 223

The compound of any one of the preceding claims, being selected from Compound Nos. 517-527 and pharmaceutically acceptable salts thereof.

### Claim 224

The compound of any one of the preceding claims, being selected from Compound Nos. 528-555 and pharmaceutically acceptable salts thereof.

### Claim 225

The compound of any one of the preceding claims, being selected from Compound Nos. 556-581 and pharmaceutically acceptable salts thereof.

### Claim 226

The compound of any one of the preceding claims, being selected from Compound Nos. 582-607 and pharmaceutically acceptable salts thereof.

### Claim 227

The compound of any one of the preceding claims, being selected from Compound Nos. 608-699 and pharmaceutically acceptable salts thereof.

### Claim 228

The compound of any one of the preceding claims, being selected from Compound Nos. 700-747 and pharmaceutically acceptable salts thereof.

### Claim 229

The compound of any one of the preceding claims, being selected from Compound Nos. 748-794 and pharmaceutically acceptable salts thereof.

### Claim 230

The compound of any one of the preceding claims, being selected from Compound Nos. 795-818 and pharmaceutically acceptable salts thereof.

### Claim 231

The compound of any one of the preceding claims, being selected from Compound Nos. 819-844 and pharmaceutically acceptable salts thereof.

### Claim 232

The compound of any one of the preceding claims, being selected from Compound Nos. 849-932 and pharmaceutically acceptable salts thereof.

### Claim 233

The compound of any one of the preceding claims, being selected from Compound Nos. 1, 5, 21, 36, 39, 42, 61, 447, 448, and 485, and pharmaceutically acceptable salts thereof.

### Claim 234

The compound of any one of the preceding claims, being selected from Compound Nos. 1, 5, 21, 36, 39, 42, 61, 447, 448, and 485.

### Claim 235

A compound being an isotopic derivative of the compound of any one of the preceding claims.

### Claim 236

A compound being an intermediate obtained by a method for preparing the compound of any one of the preceding claims.

### Claim 237

A pharmaceutical composition comprising the compound of any one of the preceding claims or a pharmaceutically acceptable salt thereof.

### Claim 238

A method of activating or enhancing acetyl-CoA synthesis in a subject comprising administering to the subject a therapeutically effective amount a compound of any one of the preceding claims.

### Claim 239

A method of increasing acetyl-CoA concentrations in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 240

A method of treating a subject having a disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 241

A method of preventing a disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 242

A method of decreasing degradation of CoA in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 243

A method of increasing the half-life of CoA in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 244

A method of prolonging the availability of CoA in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 245

A method of delivering an acyl moiety into the mitochondrial matrix of a mitochondrion of a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 246

A method of decreasing the concentration of reactive oxygen species (ROS) in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 247

A method of decreasing the concentration of an at least one acyl-CoA species in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 248

A method of increasing the fatty acid metabolism in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 249

A method of increasing the amino acid metabolism in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 250

A method of increasing mitochondrial respiration in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 251

A method of increasing ATP concentration in a subject comprising administering to the subject therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 252

A method of treating a subjecting having a cancer comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 253

A method of preventing a cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 254

A method of reducing the size of a tumor comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 255

A method of inducing tumor cell apoptosis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 256

A method of inducing cell cycle arrest in a tumor cell in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 257

A method of inducing differentiation of a cell in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 258

A method of inducing senescence in a cell in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 259

A method of enhancing an immune response against cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 260

A method of inhibiting angiogenesis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 261

A method of enhancing the apoptotic effect of an anti-cancer agent comprising administering to a subject a combination of a therapeutically effective amount of the anti-cancer agent and a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 262

A method of increasing the post-translational modification of proteins in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 263

A method of increasing acetylation of proteins in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 264

A method of increasing acetylation of histones in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 265

A method of increasing acetylation of tubulin in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 266

A method of treating a subject having a neurodegenerative disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 267

A method of preventing a neurodegenerative disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 268

A method of treating a subject having an ataxia disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 269

A method of preventing an ataxia in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 270

A method of treating nonalcoholic steatohepatitis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 271

A method of preventing nonalcoholic steatohepatitis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 272

A method of treating nonalcoholic fatty liver disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 273

A method of preventing nonalcoholic fatty liver disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 274

A method of preventing an inappropriate shift to fatty acid biosynthesis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 275

A method of treating an inflammatory disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 276

A method of preventing an inflammatory disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 277

A method of reducing inflammation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 278

A method of reducing fibrosis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 279

A method of stimulating the activity of Regulatory T cells in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 280

A method of treating Crohn's disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 281

A method of preventing Crohn's disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 282

A method of treating colitis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 283

A method of preventing colitis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 284

A method of treating chronic intestinal inflammation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 285

A method of preventing chronic intestinal inflammation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 286

A method of treating HIV in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 287

A method of treating HIV in a subject comprising administering to the subject a combination of a therapeutically effective amount of a compound of any one of the preceding claims and a therapeutically effective amount of an immune modulator compound.

### Claim 288

A method of treating HIV in a subject comprising administering to the subject a combination of a therapeutically effective amount of a compound of any one of the preceding claims and a therapeutically effective amount of an anti-HIV agent.

### Claim 289

A method of reactivating latent HIV in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 290

A method of reactivating latent HIV without inducing global T cell activation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 291

A method of treating Acute Coronary Syndrome in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 292

A method of reducing damage to cardiac cells in a subject having acute coronary syndrome comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 293

A method of reducing damage imparted by ischemia, inflammation, fibrotic remodeling or any combination thereof in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 294

A method of preventing reinfarction in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 295

A method of preventing ischemic stroke in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 296

A method of increasing the survival of cardiac cells in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 297

A method of treating major depressive disorder in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 298

A method of preventing major depressive disorder in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 299

A method of reversing acetylation patterns induced by major depressive disorder in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 300

A method of augmenting the therapeutic effect of an anti-depressant compound in a subject comprising administering to the subject a combination of a therapeutically effective amount of the anti-depressant compound and a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 301

A method of improving mitochondrial health in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 302

A method of reducing neuroinflammation in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 303

A method of improving neuronal function comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 304

A method of improving neuronal survival comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 305

A method of inhibiting microglial-mediated neuroinflammation comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 306

A method of treating a subject having Huntington's disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 307

A method of preventing Huntington's disease in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 308

A method of re-establishing CoA homeostasis in a subject comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 309

The compound of any one of the preceding claims for use in increasing acetyl-CoA concentrations in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 310

A use of the compound of any one of the preceding claims for the manufacture of a medicament for increasing acetyl-CoA concentrations in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 311

The compound of any one of the preceding claims for use in treating a disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 312

A use of the compound of any one of the preceding claims for the manufacture of a medicament for treating a disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 313

The compound of any one of the preceding claims for use in preventing a disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 314

A use of the compound of any one of the preceding claims for the manufacture of a medicament for preventing a disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 315

The compound of any one of the preceding claims for use in treating a cancer in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 316

A use of the compound of any one of the preceding claims for the manufacture of a medicament for treating a cancer in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 317

The compound of any one of the preceding claims for use in preventing a cancer in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 318

A use of the compound of any one of the preceding claims for the manufacture of a medicament for preventing a cancer in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 319

The compound of any one of the preceding claims for use in treating an inflammatory disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 320

A use of the compound of any one of the preceding claims for the manufacture of a medicament for treating an inflammatory disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 321

The compound of any one of the preceding claims for use in preventing an inflammatory disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 322

A use of the compound of any one of the preceding claims for the manufacture of a medicament for preventing an inflammatory disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 323

The compound of any one of the preceding claims for use in treating a neurodegenerative disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 324

A use of the compound of any one of the preceding claims for the manufacture of a medicament for treating a neurodegenerative disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 325

The compound of any one of the preceding claims for use in preventing a neurodegenerative disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 326

A use of the compound of any one of the preceding claims for the manufacture of a medicament for preventing a neurodegenerative disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 327

A method of treating a subject having multiple sclerosis comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 328

A method of treating a subject having epilepsy comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 329

A method of treating a subject having schizophrenia comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 330

A method of restoring acetylation of proteins from a hypo-acetylated state comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 331

A compound of any one of the preceding claims for use in treating an acute kidney injury in a subject, wherein the acetyl-CoA precursor is for administration to the subject in at least one therapeutically effective amount.

### Claim 332

A compound of any one of the preceding claims for the manufacture of a medicament for treating an acute kidney injury in a subject, wherein the acetyl-CoA precursor is for administration to the subject in at least one therapeutically effective amount.

### Claim 333

A compound of any one of the preceding claims for use in preventing an acute kidney injury in a subject, wherein the acetyl-CoA precursor is for administration to the subject in at least one therapeutically effective amount.

### Claim 334

A compound of any one of the preceding claims for the manufacture of a medicament for preventing an acute kidney injury in a subject, wherein the acetyl-CoA precursor is for administration to the subject in at least one therapeutically effective amount.

### Claim 335

A method of treating a subject having a mitochondrial disease comprising administering to the subject a therapeutically effective amount of a compound of any one of the preceding claims.

### Claim 336

A compound of any one of the preceding claims for the manufacture of a medicament for treating a mitochondrial disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.

### Claim 337

A compound of any one of the preceding claims for use in treating a mitochondrial disease in a subject, wherein the compound is for administration to the subject in at least one therapeutically effective amount.
